Biogen cuts the price tag on its Alzheimer’s drug in half
By TOM MURPHY AP Health Writer Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually. The drugmaker said Monday that starting in January it will cut the wholesale acquisition cost of the drug by about 50%. That means
Continue Reading